Lapsi Health is a health‑technology company building AI‑driven sound‑based medical devices and software that convert auscultatory body sounds into digital biomarkers for clinicians and remote care settings[1][3]. Their product suite centers on a wireless digital stethoscope and platform that *listens, documents, and analyzes* heart and lung sounds in real time to aid diagnosis, monitoring, and documentation workflows[8][4].
High‑Level Overview
- Mission: Lapsi aims to transform traditional auscultation into objective, quantifiable digital biomarkers to improve point‑of‑care decision‑making and extend monitoring beyond clinics[1][3].
- Investment philosophy / key sectors (for an investor profile): N/A — Lapsi is a portfolio company/healthtech startup focused on medical devices, digital biomarkers, and clinical AI rather than an investment firm[1][3].
- What product it builds: A multimodal digital stethoscope hardware plus cloud/AI software that performs auscultatory sound capture, automated documentation (AI scribe), and real‑time auscultation analytics for cardiac and pulmonary findings[8][4].
- Who it serves: Clinicians and healthcare providers (point‑of‑care settings), remote care and telehealth workflows, and clinical research/monitoring use cases[1][6].
- What problem it solves: Reduces subjectivity and variability in manual auscultation, speeds documentation, surfaces pathology (e.g., murmurs, abnormal lung sounds) as digital biomarkers, and enables continuous or remote monitoring outside traditional settings[1][8].
- Growth momentum: Founded in 2022, the company has progressed through prototype generations, earned ISO 13485 certification, raised early funding and grants, expanded teams and offices in Amsterdam/Helsinki (and presence in Houston), and launched FDA‑cleared Keikku 2.0 in 2025 incorporating integrated AI scribe and real‑time analytics[5][6][4].
Origin Story
- Founding year and team: Lapsi Health was founded in 2022 by a team that includes physicians and entrepreneurs — CEO/co‑founder Jhonatan Bringas Dimitriades, co‑founder Diana van Stijn, and other leaders combining clinical and engineering expertise[4][6].
- How the idea emerged: Founders aimed to modernize the stethoscope by turning auscultatory sounds into measurable digital biomarkers using AI, addressing the subjectivity of traditional auscultation and enabling remote monitoring and better clinical decision support[1][3].
- Early traction / pivotal moments: Early prototype iterations and pilot demonstrations through 2022–2023, a €700K pre‑seed close and Eurostars grant for development, ISO 13485 certification in 2024, seed funding led by Modi Ventures, and advisory board additions helped move the product toward commercialization and regulatory clearance leading to the Keikku 2.0 launch and FDA clearance in 2025[6][5][4].
Core Differentiators
- Multimodal device + integrated AI scribe: Keikku 2.0 combines auscultation, automated clinical documentation, and AI diagnostics in one device—positioning it as both a clinical tool and workflow accelerator for clinicians[4].
- Focus on *digital biomarkers* from sound: Lapsi’s platform emphasizes extracting quantifiable biomarkers from heart and lung sounds, not just recording audio, enabling structured clinical insights and longitudinal monitoring[1][3].
- Regulatory and quality progress: ISO 13485 certification and subsequent FDA clearance for Keikku 2.0 strengthen its credibility as a medical‑grade device maker[5][4].
- Hardware + software ecosystem: Offers a hardware puck‑style digital stethoscope with cloud processing and native applications for clinical integration—designed for point‑of‑care and remote monitoring workflows[8][1].
- Clinical leadership in founding team: Physician founders and advisors with expertise in digital therapeutics and clinical research inform product design and clinical validation strategies[6][5].
Role in the Broader Tech Landscape
- Trend alignment: Lapsi rides two concurrent trends — digitization of traditional medical tools (smart stethoscopes) and the rise of digital biomarkers and clinical AI for earlier, data‑driven decisions[1][8].
- Timing: Growing telehealth adoption, demand for clinician efficiency (reduction of documentation burden), and regulatory acceptance of AI/medical devices create an opportune window for clinically validated, workflow‑integrated tools[4][5].
- Market forces: Aging populations, expanded remote care, and interest in decentralized clinical trials favor objective, portable monitoring solutions that can convert physiological signals into actionable data[6][1].
- Influence: By producing regulatory‑cleared, workflow‑capable devices that bundle capture, analysis, and documentation, Lapsi could accelerate clinician adoption of sound‑based biomarkers and set a bar for integrated device + AI solutions in frontline care[4][5].
Quick Take & Future Outlook
- What’s next: Commercial rollout and scaling of Keikku 2.0 in clinical settings, additional algorithm expansion for more pathologic sounds and indications, integrations with EHRs and telehealth platforms, and international market expansion from their Amsterdam/Houston/Helsinki footprint[4][1].
- Shaping trends: Continued validation studies and regulatory approvals will determine how rapidly auscultatory digital biomarkers are accepted for diagnosis, monitoring, and remote trials; Lapsi’s ISO and FDA milestones position it well but execution and clinical evidence will be decisive[5][4].
- Potential impact: If Lapsi sustains clinical validation, reimbursement pathways, and seamless EHR integration, it could meaningfully reduce diagnostic variability, lower barriers to remote monitoring, and help normalize sound‑derived digital biomarkers in routine care[1][8].
Quick reminder: this profile synthesizes company filings, press releases, and industry reporting; specific financials and private fundraising details are summarized from available coverage and may not reflect the most recent rounds beyond cited sources[6][4].
